In a statement, CEO of VBL Therapeutics, Dror Harats, M.D, said, “Our research has shown that MOSPD2 plays a key role in the regulation of cell motility.We have generated data indicating that MOSPD2 is required for directional movement, or chemotaxis, of tumor cells and certain immune cells, and therefore appears to play a central role in both oncology and inflammation. We continue to advance our exciting VB-600 series of antibodies as drug candidates for oncology and inflammatory indications.” Shares of VBL Therapeutics are up about 47% to $3.20 per share in after-hours trading.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.